Your browser doesn't support javascript.
loading
Strengthening resistance testing for tuberculosis in India - Investment cost, throughput, and efficiency of new laboratories.
Bashir, Saima; Sarin, Sanjay; Chadha, Sarabjit Singh; Kalra, Aakshi; ThekkePurakkal, Akhil S; Duraisamy, Karthickeyan; Saacks, Sharon; Gwaza, Gamuchirai P; Ongarello, Stefano; Denkinger, Claudia M.
Afiliação
  • Bashir S; Division of Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany. Electronic address: saima.arif@uni-heidelberg.de.
  • Sarin S; FIND, India.
  • Chadha SS; FIND, India.
  • Kalra A; FIND, India.
  • ThekkePurakkal AS; FIND, India.
  • Duraisamy K; FIND, India.
  • Saacks S; FIND, the Global Alliance for Diagnostics, Geneva, 1202, Switzerland.
  • Gwaza GP; FIND, the Global Alliance for Diagnostics, Geneva, 1202, Switzerland.
  • Ongarello S; FIND, the Global Alliance for Diagnostics, Geneva, 1202, Switzerland.
  • Denkinger CM; Division of Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Germany; German Centre for Infection Research (DZIF), Partner Site Heidelberg University Hospital, Heidelberg, Germany.
Tuberculosis (Edinb) ; 136: 102245, 2022 09.
Article em En | MEDLINE | ID: mdl-35961095
ABSTRACT
A lack of laboratory capacity for drug-resistant tuberculosis (DR-TB) testing is a major barrier to DR-TB control. To overcome this barrier, the Central Tuberculosis Division (CTD), Ministry of Health and Family Welfare (MoHFW), Government of India (GoI), and FIND India established a partnership under the National Tuberculosis Elimination Program (NTEP) to strengthen and expand tuberculosis (TB) laboratory diagnostic capabilities. This partnership has led to the establishment of 61 culture & DST laboratories, increasing the testing capacity to a capability of performing over 200,000 liquid cultures and over 170,000 molecular drug sensitivity tests annually. In this study, we assess the data on throughput, efficiency, investment cost, and the capacity of the laboratory services supported by this partnership to understand impact and inform future resource allocation. We estimated the technical efficiency using Stochastic Frontier Analysis (SFA). Our results show that the established laboratory network is operating at 69% efficiency, with the capacity to perform an additional 450,000 cultures and 180,000 first-line molecular drug-susceptibility tests by 2025. This additional capacity, together with current efforts to enhance the laboratory network, has the potential to make a significant contribution to NTEP's TB elimination target by 2025.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Tuberculose Resistente a Múltiplos Medicamentos / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Tuberculose Resistente a Múltiplos Medicamentos / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article